scholarly journals Effect of angiotensin II receptor blockers on blood pressure changes at daily monitoring depending on morning or evening reception

2019 ◽  
Vol 26 (2) ◽  
pp. 32-47
Author(s):  
O. L. Rekovets ◽  
Yu. M. Sirenko ◽  
O. O. Torbas ◽  
O. O. Kushnir ◽  
G. F. Prymak

The aim – to evaluate the effect of angiotensin II receptor blockers olmesartan, azilsartan and telmisartan when administered in the morning or evening hours on blood pressure (BP) indices during daily monitoring in patients with arterial hypertension (AH). Materials and methods. The study involved 126 patients with mild to moderate hypertension who were selected to compare the effect of angiotensin II receptor blockers – olmesartan, azilsartan and telmisartan – in the morning and evening hours. They were divided into 6 groups: 20 patients taking olmesartan at a dose of 20–40 mg in the morning, 20 patients taking olmesartan at a dose of 20–40 mg in the evening, 21 patients taking azilsartan at a dose of 40–80 mg in the morning, 20 patients taking azilsartan at a dose of 40–80 mg in the evening, 22 patients taking telmisartan at a dose of 40–80 mg in the morning, 23 patients taking telmisartan at a dose of 40–80 mg in the evening. Patients underwent primary examination and repeated one – after 3 months of therapy. Results and discussion. Evening reception of olmesartan, compared with morning one, led to a more pronounced decrease in diurnal systolic blood pressure (SBT) – (11.09±2.30) vs (4.06±2.25) mm Hg (p<0.01). Changes in diurnal diastolic blood pressure (DBP) were statistically insignificant, although its decrease during evening reception was more significant compared to decrease during morning reception ((8.38±2.58) mm Hg versus (3.38±2.31) mm Hg). Changes in daily blood pressure against reception of azilsartan in the evening and morning hours were statistically significant, but did not differ from each other ((13.06±2.65)/(9.76±1.73) vs. (12.71±1.62)/(7.00±1.50) mm Hg). Reduction of diurnal blood pressure at the background of telmisartan administration was statistically significantly more pronounced in the morning than in the evening intake ((16.48±2.86)/(12.56±2.80) vs. (4.93±1.53)/(5.40±1.89) mm Hg, p<0.01). Thus, morning reception more significantly lowered the average daily blood pressure against the background of taking telmisartan, and the evening reception – against the background of taking olmesartan. Azilsartan equally reduced the blood pressure both at evening and morning admission. The rate of achievement of target BP at daily monitoring against the background of the administration of olmesartan, azilsartan and telmisartan was 71.80; 71.0 and 75.61 %, respectively. Conclusions. Admission of telmisartan more significantly reduced the average daily blood pressure in morning hours compared to evening hours, olmesartan better lowered the average daily blood pressure when taken in the evening, and the use of azilsartan equally affected the decrease in blood pressure regardless of the time of taking the drug.

2019 ◽  
Vol 26 (5) ◽  
pp. 23-32
Author(s):  
O. L. Rekovets ◽  
Yu. M. Sirenko ◽  
O. O. Torbas ◽  
C. M. Kushnir ◽  
G. F. Prymak

The aim – to evaluate the effect of angiotensin II receptor blockers – olmesartan, azilsartan and telmisartan – taken in the morning or evening hours, on office, central blood pressure under daily monitoring and to assess circadian blood pressure. Materials and methods. The study included 126 patients with mild to moderate hypertension that were selected to compare the effect of drug pharmacotherapy with angiotensin II receptor blockers – olmesartan, azilsartan and telmisartan on morning and evening hours. Patients were distributed into 6 groups: 1st group 20 patients taking olmesartan 20–40 mg in the morning, 2nd group – 20 patients taking olmesartan 20–40 mg in the evening hours, 3rd – 21 patients taking azilsartan 40–80 mg in the morning, 4th – 20 patients taking azilsartan 40–80 mg in the evening, 5th – 22 patients taking telmisartan 40–80 mg in the morning, 6th – patients taking telmisartan 40–80 mg in the evening. Patients underwent primary and re-examination followed 3 months of the therapy. Results and discussion. Lowering of office SBP/DBP in the olmesartan intake group in the evening hours was – 20.95/13.50 mm Hg (p<0.05), and when taken in the morning hours – 19.40/8.95 mm Hg (p<0.05). In the group of azіlsartan therapy, the lowering of office SBP/DBP in the evening hours was 21.10/11.50 mm Hg (p<0.05), and taken in the morning hours – 20.05/12.23 mm Hg (p<0.05). In the telmisartan intake group, the lowering of office SBP/DBP during in the evening was 19.54/9.00 mm Hg (p<0.05), and taken in the morning hours – 21.22/12.29 mm Hg (p<0.05). Lowering of central blood pressure was equally effective and did not depend on the time of taking the drugs. Lowering of central SBP with olmesartan intake was 3 months after administration in the evening hours – 18.34 mm Hg, in the morning – 15.22 mm Hg, while taking azilsartan – respectively 15.59 and 19.24 mm Hg, while taking telmisartan – respectively 12.00 and 18.00 mm Hg. Reaching of the target office blood pressure with olmesartan therapy was observed in 77.50 % of patients, with azilsartan in 78.05 % of patients, and with telmisartan in 78.57 % of patients. The intake of olmesartan, azilsartan and telmisartan did not statistically significantly affect the circadian blood pressure. Conclusions. The use of olmesartan, azilsartan and telmisartan equally effectively lowered office and central blood pressure when taken both in the morning and evening hours, and did not have a statistically significant effect on changes in blood circadian pressure.


Author(s):  
Varun Gupta ◽  
Pooja Singh

Background: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are being used as first line agents for the treatment of hypertension in haemodialysis patients as well as in the general population. Serious hyperkalemia is common in patients with end-stage renal disease, and is observed in about 10% of haemodialysis patients. Although many research have been done so far to compare the antihypertensive efficacy of ARBs, but such studies to evaluate the effect on serum urea, creatinine and potassium levels are not so common in North India region.Methods: In this open label, prospective, randomized study, we evaluated the effect on serum urea, creatinine and potassium levels with use of ARB’s (olmesartan or telmisartan) in stage 1 hypertensive patients (JNCVII). 60 patients were randomized in to two groups. The odd numbers will be allotted olmesartan 20 mg (group A) and even numbers to telmisartan 40 mg (group B). Impacts on serum urea, creatinine and potassium levels were evaluated after 12 weeks.Results: Our results indicates that there was no statistically significant alterations in mean serum creatinine, blood urea and in mean serum potassium levels compared to baseline within the two groups as well as when mean of both groups were compared, olmesartan showed a better reduction in blood pressure as compared to telmisartan.Conclusions: Olmesartan showed a better reduction in blood pressure with similar effects in biochemical parameters as telmisartan.


2013 ◽  
Vol 10 (2) ◽  
pp. 53-56
Author(s):  
O D Ostroumova ◽  
A A Zykova ◽  
T A Polosova ◽  
O V Bondarets

The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.


Sign in / Sign up

Export Citation Format

Share Document